University of Vermont Cancer Center Member Profile
Diego Adrianzen Herrera, MD
Associate Director of Diversity, Equity, and Inclusion for the UVM Cancer Center
Assistant Professor, Medicine-Hematology Oncology
Full Member
Cancer Host and Environment (CHE)
Academic Interests
Dr. Adrianzen-Herrera's research focuses on health outcomes and translational epidemiology on hematologic cancer. He has focused on using large population database and administrative claim analysis to study health outcomes among patients with myelodysplastic syndromes and other hematologic cancers. He also explores large cohort data to understand the link between cytopenia, hematologic cancer and cardiovascular disease.
Other Titles, Distinctions and Appointments
Dr. Adrianzen-Herrera is a scholar of the American Society of Hematology’s Clinical Research Training Institute and was named the UVM’s Department of Medicine Green and Gold Early Career Professor in 2021.
Postdoctoral Training
2019..... Hematology & Medical Oncology Fellowship, Albert Einstein College of Medicine, New York
2016..... Internal Medicine Residency, Ichan School of Medicine at Mount Sinai, New York
Education
2011..... Cayetano Heredia University, Lima, Peru; MD
Publications
To view more and/or the most recent publications by Diego Adrianzen Herrera please visit their biblography here.
Characteristics and survival of secondary acute myeloid leukemia arising from myelodysplastic syndrome (MDS-sAML).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19075-e19075
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
AH Bazarbachi, D Reef, H Narvel, R Patel, R Al Hamed, S Vikash, ...
Clinical Hematology International, 1-14
Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19076-e19076
Dr. Adrianzen-Herrera's research focuses on health outcomes and translational epidemiology on hematologic cancer. He has focused on using large population database and administrative claim analysis to study health outcomes among patients with myelodysplastic syndromes and other hematologic cancers. He also explores large cohort data to understand the link between cytopenia, hematologic cancer and cardiovascular disease.
Other Titles, Distinctions and Appointments
Dr. Adrianzen-Herrera is a scholar of the American Society of Hematology’s Clinical Research Training Institute and was named the UVM’s Department of Medicine Green and Gold Early Career Professor in 2021.
Postdoctoral Training
2019..... Hematology & Medical Oncology Fellowship, Albert Einstein College of Medicine, New York
2016..... Internal Medicine Residency, Ichan School of Medicine at Mount Sinai, New York
Education
2011..... Cayetano Heredia University, Lima, Peru; MD
Publications
To view more and/or the most recent publications by Diego Adrianzen Herrera please visit their biblography here.
Characteristics and survival of secondary acute myeloid leukemia arising from myelodysplastic syndrome (MDS-sAML).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19075-e19075
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
AH Bazarbachi, D Reef, H Narvel, R Patel, R Al Hamed, S Vikash, ...
Clinical Hematology International, 1-14
Effect of hypomethylating agent (HMA) exposure on survival of secondary acute myeloid leukemia (sAML) from myelodysplastic syndrome (MDS).
DA Adrianzen Herrera, A Sparks, A Batra, NA Zakai
Journal of Clinical Oncology 41 (16_suppl), e19076-e19076